AN2 Therapeutics director awarded 20,400 options

Zakrzewski Joseph S reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Zakrzewski Joseph S reported acquisition or exercise transactions in this Form 4 filing.

AN2 Therapeutics director Joseph S. Zakrzewski reported receiving a grant of stock options for 20,400 shares on February 20, 2026. These options were awarded at no purchase price on the grant date and represent his total reported derivative holdings of 20,400 options after the transaction.

According to the disclosure, the option shares will vest on February 20, 2027, provided he continues to provide service to the company through that date. This filing reflects an equity-based compensation award rather than an open‑market purchase or sale.

Insider Trade Summary

Grant/Award: 20,400 shares

Grant/Award 1 txn

Insider Zakrzewski Joseph S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,400	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 20,400 contracts (Direct)

Footnotes (1)

1. F1. The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AN2 Therapeutics (ANTX) report for Joseph S. Zakrzewski?

AN2 Therapeutics reported that director Joseph S. Zakrzewski received a grant of 20,400 stock options on February 20, 2026. The Form 4 shows this as an award-type acquisition, not an open-market buy or sell of common shares.

How many stock options were granted to the ANTX director in this Form 4?

The director was granted 20,400 stock options. The filing states this amount as the transaction size and also as the total derivative securities held by the reporting person following the transaction, indicating the full position comes from this award.

When do Joseph S. Zakrzewski’s AN2 Therapeutics stock options vest?

The option shares vest on February 20, 2027. Vesting is contingent on the reporting person providing continuous service to AN2 Therapeutics through that date, according to the footnote included with the Form 4 disclosure.

Did the ANTX director pay a purchase price for the 20,400 stock options?

The reported transaction price per share is 0.0000, indicating no cash purchase price was paid at grant. This is typical for equity awards classified as option grants or compensation, rather than open-market purchases of existing common stock.

Is the AN2 Therapeutics Form 4 transaction a buy or a sale of shares?

The transaction is classified as an acquisition via grant or award, not a buy or sale in the market. The Form 4 uses code “A” and describes it as a grant, award, or other acquisition of derivative securities.

What is Joseph S. Zakrzewski’s reported derivative holdings in ANTX after this grant?

After the grant, the filing shows total derivative securities of 20,400 stock options. This matches the number of option shares awarded in the transaction, indicating his reported derivative position consists of this single grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 04:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zakrzewski Joseph S

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.04	02/20/2026		A		20,400		(1)	02/19/2036	Common Stock	20,400	$0	20,400	D

Explanation of Responses:

1. The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date.

	/s/ Lucy Day, Attorney-in-Fact for Joseph S. Zakrzewski	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.